Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors

Enzyme-Activated Generation of Reactive Oxygen Species from Heterocyclic N-Oxides under Aerobic and Anaerobic Conditions and Its Relevance to Hypoxia-Selective Prodrugs

(2019) Xiulong Shen et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Using Properties of Tumor Microenvironments for Controlling Local, On-Demand Delivery from Biopolymer-Based Nanocarriers

(2018) Abdullah K. Alshememry et al.   CURRENT PHARMACEUTICAL DESIGN

Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides

(2018) Muriel Bonnet et al.   JOURNAL OF MEDICINAL CHEMISTRY

Passive Permeability of Planar Lipid Bilayers to Organic Anions

(2018) Andrea Ebert et al.   BIOPHYSICAL JOURNAL

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice

(2017) Yongchuan Gu et al.   Frontiers in Pharmacology

Radical Chemistry and Cytotoxicity of Bioreductive 3-Substituted Quinoxaline Di-N-Oxides

(2016) Robert F. Anderson et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs

(2015) F. W. Hunter et al.   CANCER RESEARCH

The Clinical Significance of Hypoxia in Human Cancers

(2015) Neesha Dhani et al.   SEMINARS IN NUCLEAR MEDICINE

Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5

(2014) Jingli Wang et al.   BIOCHEMICAL PHARMACOLOGY

The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs

(2014) Francis W. Hunter et al.   BIOCHEMICAL PHARMACOLOGY

Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer

(2014) F. W. Hunter et al.   MOLECULAR CANCER THERAPEUTICS

Passive Lipoidal Diffusion and Carrier-Mediated Cell Uptake Are Both Important Mechanisms of Membrane Permeation in Drug Disposition

(2014) Dennis Smith et al.   MOLECULAR PHARMACEUTICS

Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000

(2014) Robert F. Anderson et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion

(2014) Douglas B. Kell et al.   Frontiers in Pharmacology

Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy

(2013) Jin-Zhi Du et al.   BIOTECHNOLOGY ADVANCES

Acidity Generated by the Tumor Microenvironment Drives Local Invasion

(2013) V. Estrella et al.   CANCER RESEARCH

Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence

(2013) Jiechuang Su et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104

(2013) Annika Foehrenbacher et al.   Frontiers in Oncology

A Gynecologic Oncology Group phase III randomized trial of weekly cisplatin and radiation versus cisplatin and tirapazamine and radiation in stage IB2, IIA, IIIB and IVA cervical carcinoma limited to the pelvis

(2012) P. DiSilvestro et al.   GYNECOLOGIC ONCOLOGY

Plasma membrane electron transport in pancreatic β-cells is mediated in part by NQO1

(2011) Joshua P. Gray et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia

(2011) J. Wang et al.   CLINICAL CANCER RESEARCH

Interfering with pH regulation in tumours as a therapeutic strategy

(2011) Dario Neri et al.   NATURE REVIEWS DRUG DISCOVERY

Acidic Environment Leads to ROS-Induced MAPK Signaling in Cancer Cells

(2011) Anne Riemann et al.   PLoS One

Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors

(2010) K. O. Hicks et al.   CLINICAL CANCER RESEARCH

Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer

(2010) Johanna Chiche et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

(2010) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of Radicals Formed Following Enzymatic Reduction of 3-Substituted Analogues of the Hypoxia-Selective Cytotoxin 3-Amino-1,2,4-Benzotriazine 1,4-Dioxide (Tirapazamine)

(2010) Sujata S. Shinde et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Tumour–stromal interactions in acid-mediated invasion: A mathematical model

(2010) Natasha K. Martin et al.   JOURNAL OF THEORETICAL BIOLOGY

Spin Trapping of Radicals Other Than the•OH Radical upon Reduction of the Anticancer Agent Tirapazamine by Cytochrome P450Reductase

(2009) Sujata S. Shinde et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators

(2009) W. R. Wilson et al.   MOLECULAR CANCER THERAPEUTICS

Tricyclic [1,2,4]Triazine 1,4-Dioxides As Hypoxia Selective Cytotoxins

(2008) Michael P. Hay et al.   JOURNAL OF MEDICINAL CHEMISTRY

Initiation of DNA Strand Cleavage by 1,2,4-Benzotriazine 1,4-Dioxide Antitumor Agents: Mechanistic Insight from Studies of 3-Methyl-1,2,4-benzotriazine 1,4-Dioxide

(2008) Venkatraman Junnotula et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression

(2008) Jennifer S. Fang et al.   SEMINARS IN CANCER BIOLOGY